References
- A. Cipriani, JM. Rendell, J. Geddes, Olanzapine in long-term treatment for bipolar disorder, The Cochrane Database of Systematic Reviews 1 (2009) CD004367. DOI: 10.1002/14651858.CD004367.pub2
- K. Komoss, C. Rummel-Kluge, H. Hunger, F. Schmid, S. Schwarz, L. Duggan, W. Kissling, S. Leucht, Olanzapine versus other atypical antipsychotics for schizophrenia, The Cochrane Database of Systematic Reviews 3 (2010) CD006654. DOI: 10.1002/14651858.CD006654.pub2
- P.F. Buckley, Olanzapine: a critical review of recent literature, Expert Opinion on Pharmacotherapy 6 (2005) 2077-2089. DOI: 10.1517/14656566.6.12.2077
- L. Duggan, M. Fenton, J. Rathbone, R. Dardennes, A. El-Dosoky, S. Indran, Olanzapine for schizophrenia, The Cochrane Database of Systematic Reviews 2 (2005) CD001359. DOI: 10.1002/14651858.CD001359.pub2
- E. Vieta, Olanzapine in bipolar disorder, Expert Opinion on Pharmacotherapy 5 (2004) 1613–1619. DOI: 10.1517/14656566.5.7.1613
- B.J. Ring, J. Catlow, T.J. Lindsay, T. Gillespie, L.K. Roskos, B.J. Cerimele, S.P. Swanson, M.A. Hamman, S.A. Wrighton, Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine, The Journal of Pharmacology and Experimental Therapeutics 276 (1996) 658-666.
- M.M. Söderberg, M.L. Dahl, Pharmacogenetics of olanzapine metabolism, Pharmacogenomics 14 (2013) 1319-1336. DOi: 10.2217/pgs.13.120
- J. Guo, X. Zhu, S. Badawy, A. Ihsan, Z. Liu, C. Xie, X. Wang, Metabolism and mechanism of human cytochrome P450 enzyme 1A2, Current Drug Metabolism 22 (2021) 40-49. DOI: 10.2174/1389200221999210101233135
- V.K. Jogiraju, T. Heimbach, Y. Toderika, D.R. Taft, Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumption, Drug Metabolism and Pharmacokinetics 37 (2021) 100375. DOI: 10.1016/j.dmpk.2020.100375
- T.C. Peterson, M.R. Peterson, P.A. Wornell, M.G. Blanchard, F.J. Gonzalez, Role of CYP1A2 and CYP2E1 in the pentoxifylline ciprofloxacin drug interaction, Biochemical Pharmacology 68 (2004) 395-402. DOi: 10.1016/j.bcp.2004.03.035
- T.I. Prior, G.B. Baker, Interactions between the cytochrome P450 system and the second-generation antipsychotics, Journal of Psychiatry & Neuroscience 28 (2003) 99-112.
- L. Zhang, M.J. Wei, C.Y. Zhao, H.M. Qi, Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes, Acta Pharmacologica Sinica 29 (2008) 1507-1514. DOI: 10.1111/j.1745-7254.2008.00908.x
- M.T. Granfors, J.T. Backman, M. Neuvonen, P.J. Neuvonen, Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism, Clinical Pharmacology and Therapeutics 76 (2004) 598-606. DOI: 10.1016/j.clpt.2004.08.018
- F. Pea, M. Furlanut, Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions, Clinical Pharmacokinetics 40 (2001) 833-868. DOI: 10.2165/00003088-200140110-00004
- A.M. Gheldiu, D.M. Muntean, I. Cristea, I. Antonescu, R. Chira, C. Ureche, L. Vlase, Kinetics of Nebivolol and its active metabolite after single dose oral administration of Nebivolol, Revista de Chimie (Bucharest) 67 (2016) 702-705.
- A.M. Gheldiu, A. Csavdari, M. Achim, L. Vlase, I. Tomuță, D. Muntean, Kinetics of zolpidem and its metabolite after single dose oral administration of zolpidem, Studia UBB Chemia LXII (2017) 179-188. DOI: 10.24193/subbchem.2017.2.13
- M. Oroian, A. Marcovici, D.I. Pop, S. Bhardwaj, A. Khuroo, A.M. Gheldiu, L. Vlase, Kinetics of dapagliflozin after single dose oral administration of a 10 mg immediate release tablet, Studia UBB Chemia LXIV (2019) 297-308. DOI: 10.24193/subbchem.2019.2.25
- D.I. Pop, A. Marcovici, M. Oroian, A.M. Gheldiu, L. Vlase, Kinetics of gliclazide after single dose oral administration of gliclazide 60 mg modified release tablet, Studia UBB Chemia LXV (2020) 187-196. DOI: 10.24193/subbchem.2020.2.15
- C. Dansirikul, M. Choi, S.B. Duffull, Estimation of pharmacokinetic parameters from noncompartmental variables using Microsoft Excel, Computers in Biology and Medicine 35 (2005) 389-403. DOI: 10.1016/j.compbiomed.2004.02.008
- W.R. Gillespie, Noncompartmental versus compartmental modelling in clinical pharmacokinetics, Clinical Pharmacokinetics 20 (1991) 253-262. DOI: 10.2165/00003088-199120040-00001
- A. Rescigno, Compartmental analysis and its manifold applications to pharmacokinetics, The AAPS Journal 12 (2010) 61-72. DOI: 10.1208/s12248-009-9160-x
- G. Glatting, P. Kletting, S.N. Reske, K. Hohl, C. Ring, Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test, Medical Physics 34 (2007) 4285-4292. DOI: 10.1118/1.2794176
- H. Akaike, A new look at the statistical model identification, IEEE Transactions on Automatic Control 19 (1974) 716-723. DOI: 10.1109/TAC.1974.1100705